ADC Manufacturing Will Likely Stay with Established CDMOs Due to High Barrier to Market Entry

Antibody-drug conjugate (ADCs) manufacturing is likely to remain among CDMOs already making them due to demanding market entry requirements, executives in the ADC space said. ADC toxicity requires extra care in production, with staff training and equipment needed beyond traditional manufacturing for chemotherapies and antibodies, they added. “CDMOs of all sizes probably see the current market potential for development and manufacture of ADCs, but the ability to enter the space efficiently is limited for many,” added Roger Lias, CCO at Aurigene Pharmaceutical Services, a CDMO with ADC manufacturing abilities.

Read the full article: ADC Manufacturing Will Likely Stay with Established CDMOs Due to High Barrier to Market Entry //

Source: https://endpts.com/adc-manufacturing-will-likely-stay-with-established-cdmos-due-to-high-barrier-to-market-entry

Leave a Comment

Your email address will not be published.

Scroll to Top